The FDA deferred its ruling on AstraZeneca's camizestrant to review analyses filed after an advisory...
FDA delays ruling on AstraZeneca drug after negative adcomm vote
The FDA deferred its ruling on AstraZeneca's camizestrant to review analyses filed after an advisory committee voted against the breast cancer asset.
Author: Fierce Biotech
Read Original Article